

Novel patient missense mutations in the *HSD17B10* gene affect dehydrogenase and mitochondrial tRNA modification functions of the encoded protein

Stephanie Oerum^a, Martine Roovers^b, Michael Leichsenring^c, Cécile Acquaviva-Bourdain^d, Frauke Beermann^e, Corinne Gemperle-Britschgi^f, Alain Fouilhoux^g, Louis Droogmans^h, Udo Oppermann^{a,i}, Jörn Oliver Sass^{*e,f,j}, Wyatt W. Yue^{*a}

^aStructural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ Oxford, UK. Stephanieoerum@gmail.com

^bInstitut de Recherches Microbiologiques Jean-Marie Wiame, Bruxelles, Belgium. Mroovers@ulb.ac.be

^cDepartment for Children and Adolescent Medicine, Ulm University Medical School, Ulm, Germany. Michael.leichsenring@uniklinik-ulm.de

^dGroupement Hospitalier Est, Centre de Biologie Est, Service Maladies Héréditaires du Métabolisme, Bron, France. Cecile.acquaviva-bourdain@chu-lyon.fr

^eUniversity of Freiburg Children's Hospital, Laboratory of Clinical Biochemistry and Metabolism, Freiburg, Germany. Fraukebeermann@web.de

^fUniversity Children's Hospital and Children's Research Center, Clinical Chemistry & Biochemistry, Zürich, Switzerland. Corinne.Gemperle@kispi.uzh.ch

^gCentre de Référence des Maladies Héréditaires du Métabolisme, HCL, Bron France. Alain.fouilhoux@chu-lyon.fr

^hLaboratoire de Microbiologie, Université libre de Bruxelles, Belgium. ldroogma@ulb.ac.be

ⁱBotnar Research Centre, NIHR Oxford Biomedical Research Unit, Oxford, UK. Udo.oppermann@sgc.ox.ac.uk

^jBonn-Rhein-Sieg University of Applied Sciences, Department of Natural Sciences, von-Liebig-Str. 20, 53359 Rheinbach, Germany

*To whom correspondence should be addressed: wyatt.yue@sgc.ox.ac.uk (TEL) or joern.oliver.sass@h-brs.de (TEL)

ABSTRACT

HSD10/MRPP2 is a multifunctional protein that harbours both catalytic and non-catalytic functions. The protein belongs to the short-chain dehydrogenase/reductases (SDR) family and is involved in the metabolism of several classes of steroids and in the catabolism of isoleucine. HSD10/MRPP2 also moonlights in a complex with the MRPP1 protein for N1-methylation of purines at position 9 of mitochondrial tRNA, and in a complex with MRPP1 and MRPP3 proteins for 5'-end processing of mitochondrial precursor tRNA. Inherited mutations in the *HSD17B10* gene encoding HSD10/MRPP2 protein lead to a childhood disorder characterised by progressive neurodegeneration, cardiomyopathy or both. Here we report two patients with novel missense mutations in the *HSD17B10* gene (c.34G>C and c.526G>A), resulting in the p.V12L and p.V176M substitutions. Val12 and Val176 are highly conserved residues located at different regions of the MRPP2 structure. Recombinant mutant proteins were expressed and characterised biochemically to investigate their effects towards the functions of MRPP2 and associated complexes *in vitro*. Both mutant proteins showed significant reduction in the dehydrogenase, methyltransferase and tRNA processing activities compared to wildtype, associated with reduced stability for protein with p.V12L, whereas the protein carrying p.V176M showed impaired kinetics and complex formation. This study therefore identified two distinctive molecular mechanisms to explain the biochemical defects for the novel missense patient mutations.

Running title: Biochemical characterisation of two novel HSD10 mutations

Abbreviations: HSD10: 17 β -hydroxysteroid dehydrogenase type 10, MRPP1: mitochondrial ribonuclease P protein subunit 1, MRPP2: mitochondrial ribonuclease P protein subunit 2, MRPP3: mitochondrial ribonuclease P protein subunit 3, SDR: short-chain dehydrogenase/reductases, L-methyl-3-HAD: L-2-methyl-3-hydroxyacyl-CoA dehydrogenase, MHBD: 2-methyl-3-hydroxybutyryl-CoA dehydrogenase, (mt)RNase P: mitochondrial RNase P, pre-(mt)tRNA: precursor mitochondrial tRNA, mitochondrial tRNAs: (mt)tRNA, m¹A9: 1-methyladenosine, m¹G9, 1-methylguanosine, m¹R9: 1-methyladenosine/1-methylguanosine.

Keywords: dehydrogenase, mitochondrial tRNA, HSD10, methyltransferase, tRNA processing, MRPP

1. INTRODUCTION

17 β -hydroxysteroid dehydrogenase type 10 (HSD10; also known as mitochondrial ribonuclease P protein subunit 2, MRPP2) is a mitochondrial enzyme involved in multiple cellular pathways including fatty acid oxidation, amino acid degradation, steroid metabolism and mitochondrial tRNA maturation. HSD10/MRPP2 belongs to the family of NAD(P)(H)-dependent short-chain dehydrogenase/reductases (SDR) [1–3], and was first identified as the dehydrogenase enzyme L-2-methyl-3-hydroxyacyl-CoA dehydrogenase (L-methyl-3-HAD) that converts L-2-methyl-3-hydroxybutyryl-CoA to 2-methyl-acetoacetyl-CoA, the penultimate step of isoleucine metabolism by β -oxidation [4]. Since then, many *in vitro* SDR substrates have been identified for HSD10/MRPP2 including the sex hormone 17 β -estradiol [5,6], bile acids [7], the neurosteroid allopregnanolone [8], and short straight-chain/branched-chain fatty acyl-CoA thioesters [9]. The protein is also known to be inhibited by amyloid- β peptide [10,11].

Missense mutations of the *HSD17B10* gene encoding HSD10/MRPP2 have been shown to cause an unusual neurodegenerative childhood disorder, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency, more recently referred to as HSD10 disease [3–5]. Despite being reported only in a few patients, characterised by progressive neurodegeneration, cardiomyopathy or both, there is significant heterogeneity in the clinical manifestation [12]. A highly unusual feature of HSD10 disease that distinguishes this from other metabolic disorders is a lack of correlation between the clinical symptoms and the enzyme dehydrogenase activity, indicating a defect in other cellular pathway(s). To this end, several *HSD17B10* missense mutations lead to mitochondrial damage and apoptotic cell death [13], with defects in mitochondrial tRNA processing [14]. In line with this, HSD10/MRPP2 protein was identified to be an essential subunit of the mitochondrial RNase P ((mt)RNase P) complex responsible for processing of the 5'-end of precursor mitochondrial tRNAs (pre-(mt)tRNA), an important regulatory step in the transcription of mitochondrial DNA [15]. HSD10 was hence assigned the alternative nomenclature of MRPP2, which will be used hereafter in the manuscript.

The (mt)RNase P complex, exclusively found in metazoans, consists of MRPP2 and two other nuclear-encoded proteins: MRPP1 (*RG9MTD1* gene) and MRPP3 (*KIAA0391* gene). MRPP1 (also known as TRMT10C) belongs to the SPOUT family of RNA methyltransferases [16], whilst

MRPP3 is a Mg^{2+} -dependent endoribonuclease of the Nedd4-YacP nuclease family [17]. In addition to the RNase P activity of the ternary complex, MRPP1 and MRPP2 were found to form a binary subcomplex that methylates the N1-atom of purines at position 9 (m^1R9) in (mt)tRNAs [18]. m^1R9 modification is shown to confer stability for certain human (mt)tRNA [19–21].

To date, 13 missense patient mutations in MRPP2 have been reported (p.V65A, p.D86G, p.L122V, p.R130C, p.Q165H, p.A154T, p.A157V, p.A158V, p.P210S, p.K212E, p.R226Q, p.N247A, p.E249Q) [4,13,22–30]. Out of them, five have recently been characterised at the recombinant protein and biochemical levels [28,31]. Here we report two novel mutations identified in two families following Sanger sequencing, prompted by characteristic patterns of urine organic acids. The biochemical abnormalities of the mutated proteins were studied *in vitro* using expression, activity and binding assays. We show that the two novel mutations alter dehydrogenase activity and both tRNA modification activities (m^1R9 methylation and RNase P) of MRPP2 via different molecular mechanisms.

2. PATIENTS, MATERIALS AND METHODS

2.1 Patients

Family 1 (German):

The (male) index case first came to medical attention at age 13 months with an atonic seizure following two days of reduced dietary intake. Body temperature was at 38°C; the patient was fatigued and lips suggested cyanosis; blood glucose was elevated to 250 mg/dL, lactic acid to 8.9 mmol/L. Blood gas analysis revealed a pH of 7.373, pCO₂ of 27.3 mmHg and a base excess of -12.1 mmol/L. The major abnormality in metabolic investigations was an increase in urinary 2-methyl-3-hydroxybutyric acid, in one investigation together with an elevated signal of tiglylglycine. This was accompanied by some increase of C5:1 acylcarnitine in the acylcarnitine pattern determined in dried blood spots. The combination of clinical observations and laboratory results prompted sequence analysis of the *HSD17B10* gene. The physical and neurological development of the patient was normal, although some subcortical impairment of myelinisation, and hyperintensities in paraventricular white matter had been noted at magnetic resonance tomography. The physical and neurological development remained normal during four years of follow-up.

The index case had two older brothers. The first brother (five years older than the index case) presented with developmental impairment affecting cognition, speech development and motoric coordination. He showed growth hormone deficiency and a complex chromosomal rearrangement, but no increase in urinary 2-methyl-3-hydroxybutyric acid excretion. The second older brother (eight years older than the index case) was asymptomatic with normal physical and neurological development. For this brother, organic acids were determined in the urine and showed an increase in both 2-methyl-3-hydroxybutyric acid and tiglylglycine. During four years of follow-up, this boy showed normal physical and neurological development. Magnetic resonance tomography of the neurocranium showed no abnormalities, except a small sella. The mother of the index case was asymptomatic. A paternal sample could not be obtained.

Family 2 (French):

The (female) patient presented at 12 months of age with breaking of her weight curve (-0.5 SD at 6 months of age, -2.5 SD at 12 months of age). Her height and brain circumference remained stable. She had hypotonia and was not able to sit. She further showed cerebella ataxia, was developmentally delayed and did not speak. At 15 months of age, a systolic murmur appeared, compatible with asymptomatic dilated cardiomyopathy. At 18 months of age, a cardiac decompensation was observed which, despite treatment, led to the death of the patient at 21 months of age.

Urinary organic acid analysis showed elevated levels of 2-methyl-3-hydroxybutyric acid and tiglylglycine. Based on this profile, sequence analysis of the *HSD17B10* gene and enzyme activity testing were performed.

2.1 Mutation analysis and enzyme activity testing in patient samples

Genomic DNA was extracted from EDTA blood by standard methods. Exons 1 to 6 of the *HSD17B10* gene plus flanking intronic regions were analysed by Sanger sequencing. Assessment of the activity of L-2-methyl-3-hydroxybutyryl-CoA dehydrogenase activity in cell homogenates of fibroblasts and of lymphocytes, the latter immortalised by transformation with Epstein-Barr virus, was performed based on the description by Zschocke et al. 2000 [24].

2.2 Recombinant protein expression and purification

DNA fragments encoding human MRPP2 (MGC collection 2819721) or MRPP3 (MGC collection 5206545) were subcloned into pNIC28-Bsa4 vector (GenBank EF198106) incorporating an N-terminal His₆-tag. To generate an MRPP1-MRPP2 co-expression plasmid, a DNA fragment of human MRPP1 (MGC collection 4719195) and MRPP2, interspersed with a ribosome binding site, was subcloned into the pNIC28-Bsa vector. Constructs for MRPP2 carrying the patient missense mutations were generated by site-directed mutagenesis using the QuickChange kit (Agilent), based on the pNIC28-Bsa4 vector containing either full-length His₆-MRPP2 or both mature His₆-MRPP1 and full-length MRPP2 in a bicistronic transcript. The presence of the DNA changes was verified by Sanger sequencing.

Plasmids were transformed into *E. coli* BL21(DE3)-R3-pRARE2 competent cells, cultured in Terrific Broth at 37°C, and induced with 0.1 mM isopropyl β -D-1-thiogalactopyranoside for overnight growth at 18°C. For small-scale expression and solubility tests, cell pellets from 50 mL cultures were lysed by sonication, fractionated by centrifugation, and the resulting lysate was applied to immobilised metal affinity column (IMAC) for protein purification.

For large-scale purification for biochemical assays, MRPP2 (wildtype and mutants), co-expressed MRPP1-MRPP2 complex, and MRPP3 cell pellets from 3-12 L cultures were lysed as described above, and recombinant proteins were purified by IMAC and size exclusion chromatography, treated with Tobacco Etch Virus protease overnight, and further purified by IMAC and ion-exchange chromatography with a NaCl-gradient.

2.3 Analytical size-exclusion chromatography (SEC)

MRPP2 wildtype or mutant protein at equal amounts were injected onto a Sepax SRT SEC-300 column (Sepax Technologies) pre-equilibrated in a buffer of 500 mM NaCl, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 5% glycerol, 0.5 mM tris(2-chloroethyl) phosphate (TCEP). Protein elution was detected as a UV absorbance peak. Five proteins of known molecular weight (MW) (Bio-Rad): thyroglobulin (bovine), γ -globulin (bovine), ovalbumin (chicken), myoglobin (horse) and vitamin B₁₂, were applied to the column under the same conditions as for the protein of interest for MW determination.

2.4 Differential Scanning Fluorimetry (DSF)

DSF was performed in a 96-well plate using an Mx3005p RT-PCR machine (Stratagene) with excitation and emission filters of 492 and 610 nm, respectively. Each well consisted of 2 μ L protein in 2 μ M DSF buffer (150 mM NaCl, 10 mM HEPES pH 7.5), 2 μ L SYPRO ORANGE diluted 1000-fold in DSF buffer from the manufacturers stock (Invitrogen), and (if applicable) 2 μ L ligand at various concentrations. Fluorescence intensities were measured from 25 to 96°C with a ramp rate of 3°C/min. T_m was determined by curve-fitting using GraphPad Prism v.5.01 software, as described [32].

2.5 SDR activity assay

100 μM NAD^+ and substrate (allopregnanolone or DL-3-hydroxybutyryl-CoA) of various concentrations (100 to 0.05 μM) were mixed in a buffer of 100 mM NaCl and 20 mM Tris-HCl pH 8.0, to a final volume of 50 μL , and dispensed to 384-well plates (Corning). 3.7 μM purified MRPP2 protein (wildtype or mutant) was added and the fluorescence from NAD^+ conversion to NADH was continuously measured at 350 nm excitation/450 nm emission in a PHERAstar FSX microplate reader (BMG LABTECH) for 30 min. The obtained fluorescence data were analysed with the MARS software (BMG LABTECH) and kinetic parameters (K_M , V_{max}) were obtained by fitting data to Michaelis-Menten equation. k_{cat} was calculated for four active sites of a MRPP2 tetramer.

2.6 *In vitro* transcription of mitochondrial tRNA precursors

cDNAs representing human mitochondrial tRNA^{Ile} and tRNA^{Val} precursors were designed with leader and trailer sequences of 30 and 15 nucleotides, respectively, and *in vitro* transcribed from a PCR-amplified template by T7 RNA polymerase using the Transcript Aid T7 High yield transcription kit (Thermo Scientific). The transcribed precursor tRNAs were purified using the RNeasy Mini Kit (Qiagen).

2.7 Methyltransferase activity assay

1 μCi [methyl-³H]SAM (15 Ci/mmol) (PerkinElmer), 1 μM individual or complexed protein(s), and 1 μg *in vitro* transcribed pre-(mt)tRNA was diluted in a buffer of 50 mM Tris-HCl pH 8, 5 mM MgCl_2 , 20 mM NaCl and 1 mM DTT to 200 μL . The solution was incubated for 60 min. at 37°C in a heat block. The reaction was stopped by phenol extraction and the pre-(mt)tRNA substrate was TCA-precipitated. Radioactive methylated pre-(mt)tRNA was captured on a filter and washed three times with ethanol prior to the measurement of radioactivity in a scintillation counter.

2.8 RNase P activity assay

RNase P cleavage was performed by mixing 300 nM MRPP1-MRPP2, 150 nM MRPP3, 10 units of ribonuclease inhibitors (RNasin from Promega) and 400 nM *in vitro* transcribed pre-(mt)tRNA^{Ile} in a buffer of 30 mM Tris-HCl pH 8, 40 mM NaCl, 4.5 mM MgCl_2 and 2 mM DTT, to a total reaction volume of 8.25 μL . The reaction was performed at room temperature and stopped at

set times by transferring 1 μ L of the reaction mixture into 5 μ L 500 mM EDTA and heating to 95°C. This sample was analysed by denaturing-PAGE on a 6% TBE-urea gel (Invitrogen) run in TBE buffer (Invitrogen). The gel was stained for 30 min. with SYBRO GOLD (Invitrogen) diluted 1000-fold in TBE buffer from the manufactures stock, and imaged using the Bio-Rad ChemiDoc Imaging System.

3. RESULTS

3.1 Mutation analysis and assessment of 2-methyl-3-hydroxybutyryl-coenzyme A dehydrogenase activity

Sequence analysis of the *HSD17B10* gene in the index case of family 1, yielded hemizygosity of the mutation c.526G>A in exon 5, predicted to result in a Val176-to-Met substitution (p.V176M). Prediction programs MutationTaster, PolyPhen-2 and SIFT consider this change as “disease causing”, “probably damaging”, and “damaging”, respectively. The variant was neither found in ExAc nor in the 1000 G database. An enzyme activity assay for 2-methyl-3-hydroxybutyryl-CoA dehydrogenase, which was performed in lymphocytes transformed with Epstein-Barr virus, did not yield detectable enzyme activity. The mutation c.526G>A in the *HSD17B10* gene was also identified in the mother (heterozygote) and in the second brother (eight years older than the index case), who were both asymptomatic. In contrast, the first brother (five years older than the index case), that presented with major developmental impairment, did not have the *HSD17B10* mutation identified in his relatives.

In DNA of the patient of family 2, mutation analysis revealed the heterozygous mutation c.34G>C in exon 2 of the *HSD17B10* gene, which was not found in DNA of her parents and should result in replacement of Val12 by Leu (p.V12L). The p.V12L missense change is predicted to be “disease causing” by MutationTaster, “probably damaging” by PolyPhen-2, and “damaging” by SIFT servers. The mutation was neither found in ExAc nor in the 1000 G database. The 2-methyl-3-hydroxybutyryl-CoA dehydrogenase activity assay, which was performed in lymphocytes transformed with the Epstein-Barr virus, and in fibroblast homogenates, revealed major residual activities of 69% and 47%, respectively.

3.2 A structural annotation of known MRPP2 mutations

Residues Val12 and Val176 are highly conserved through evolution in the MRPP2 protein encoded by the *HSD17B10* gene. Including the two novel mutations reported here (p.V12L, p.V176M), there are in total 15 missense mutations reported for the HSD10 disease to date. MRPP2 forms a tetramer (dimer of dimers) with a Rossmann-fold as revealed by its crystal structure [33]. These missense mutations are distributed widely across each monomer of the

tetramer (Fig. 1.A) with locations in core structural elements, in close proximity to catalytic residues, and at monomer-monomer interfaces. Val12 is located in the central β -sheet that forms the core structure of the Rossmann-fold (Fig. 1.B). V176M is located in one of the two long α -helices (helix- α E and helix- α F) harbouring two of the catalytic residues Tyr168 and Lys172 (Fig. 1.C), and further residues involved in the proton-relay system as well as in substrate binding (Fig. A).




Fig. 1. Structural mapping of HSD10 disease mutations

(A) Sites of HSD10 patient missense mutations (green sticks) are mapped onto one monomer (yellow cartoon) of the MRPP2 tetramer (other subunits grey) (PDB: 2O23). The inset shows the architecture of the full MRPP2 tetramer. (B) Location of the p.V12L mutation (green stick) in the central β -sheet (orange). The secondary structure assignment is indicated for strand β A-G and helix α D-E. (C) Location of the p.V176M mutation. Catalytic residues (Lys172 and Tyr168) located in the same α -helical segment as the mutation site are shown as yellow sticks. NAD⁺ cofactor is shown as purple sticks. Secondary structure assignment is indicated helix α E-F.

3.3 Recombinant expression of MRPP2(V12L) and MRPP2(V176M)

To determine the effect of mutations towards the translated protein, recombinant MRPP2(WT), MRPP2(V12L) and MRPP2(V176M) were expressed in *E. coli*, and purified by affinity chromatography to compare expression and solubility levels. SDS-PAGE revealed similar levels of expression in *E. coli* for MRPP2 wildtype and mutant proteins (Fig. 2.A and B), although the solubility of MRPP2(V12L) was significantly lower than that of MRPP2(WT) and MRPP2(V176M) (Fig. 2.A and C). The purified proteins (Fig. B) were subjected to DSF to determine their thermostability (Fig. 2.D). Consistent with the reduced solubility for MRPP2(V12L), the isolated protein (melting temperature (T_m) = 47.60 ± 0.70) was found to be less thermostable than wildtype (T_m = 50.26 ± 0.34), while MRPP2(V176M) (T_m = 55.9 ± 0.25), by contrast, was more thermostable. In high-resolution analytical SEC, both MRPP2(V12L) and MRPP2(V176M) revealed the presence of an elution peak, like wildtype, that corresponds in MW to a tetramer (Fig. C). MRPP2(V12L) revealed a peak at the void volume indicative of protein aggregation, and is consistent with the observed lowered solubility.

Next, binding of the NADH cofactor was assessed for recombinant wildtype and mutant proteins using DSF. Binding of NADH to as-purified MRPP2(WT) increased its T_m (ΔT_m) by $10.24 \pm 0.16^\circ\text{C}$ (Fig. 2.F) whereas both mutant proteins showed significantly lower T_m shifts with NADH (ΔT_m = $1.60 \pm 1.0^\circ\text{C}$ for MRPP2(V12L); ΔT_m = $1.28 \pm 0.43^\circ\text{C}$ for MRPP2(V176M) (Fig. 2.E), indicating their much reduced binding affinity for NADH.




Fig. 2. Effect of p.V12L/p.V176M mutations on recombinant MRPP2 protein

(A) Intensities of SDS-PAGE bands from total lysate (S) samples of initial IMAC. (B) Intensities of SDS-PAGE bands from elution (E) fractions of initial IMAC. Wildtype (WT) is taken as 100%. (C) SDS-PAGE of the initial IMAC from which intensities for (A) and (B) were calculated. (D) Melting temperature (T_m) values for MRPP2 mutant proteins in the as-purified state. (E) Change in melting temperature (ΔT_m) upon addition of NADH to MRPP2 proteins. (F) Thermal unfolding curve for MRPP2(WT) in the as-purified form and in the presence of NAD⁺/NADH. In the DSF experiments, n=3-5. **=P<0.01, ****=P<0.0001.

3.4 Dehydrogenase activity of MRPP2 mutants

We next monitored the dehydrogenase activity of purified MRPP2 recombinant proteins (Fig. B), using two substrates that reflect the involvement of MRPP2 in fatty acid metabolism and

neurosteroid conversion. For fatty acid metabolism, the substrate 3-hydroxybutyryl-CoA, a short straight-chain 3-hydroxyacyl-CoA thioester previously shown to be turned over by MRPP2 *in vitro* using NAD⁺ [10], was used. Purified MRPP2(WT), MRPP2(V12L) and MRPP2(V176M) were active towards 3-hydroxybutyryl-CoA with similar k_{cat} values, although the K_M of MRPP2(V176M) was increased 3-fold leading to an overall 3-fold reduction in catalytic efficiency (k_{cat}/K_M), compared to wildtype (Fig. 3.A). For steroid metabolism, we assayed the NAD⁺-dependent conversion of the neurosteroid allopregnanolone to 5 α -dihydroprogesterone (5 α -DHP). MRPP2(V12L) exhibited a nearly 3-fold decrease in catalytic efficiency compared to wildtype, due to both k_{cat} and K_M effects (Fig. 3.B), while, surprisingly, MRPP2(V176M) did not turn over this substrate.




Fig. 3. Effect of p.V12L/p.V176M mutations on MRPP2 dehydrogenase activity

Michaelis-Menten plot for the catalysis of (A) (DL)-3-hydroxybutyryl-CoA and (B) allopregnanolone by MRPP2 wildtype and mutant proteins in the presence of NAD⁺. RFU: relative fluorescence units. Kinetic parameters for the two reactions are shown on the right.

3.5 Complex assembly with MRPP1

In addition to its dehydrogenase activity alone, MRPP2 is an essential subunit of the (mt)tRNA modification complexes of MRPP1-MRPP2 for purine-9 N1-methyltransferase (m¹R9) activity, and MRPP1-MRPP2-MRPP3 for 5'-end endonuclease (RNase P) activity. To determine the effect of p.V12L and p.V176M mutations towards these complexes and their associated activities, we first co-expressed each of MRPP2(WT), MRPP2(V12L) and MRPP2(V176M) with His₆-tagged MRPP1, and purified the binary complexes by IMAC. In this procedure, His₆-tagged MRPP1 pulled down similar amounts of untagged MRPP2(WT), MRPP2(V12L) and MRPP2(V176M) (Fig. D), suggesting that the mutant proteins retained the ability to form a complex with MRPP1.

To determine the relative stability of the binary complexes, equal amounts of the isolated MRPP1-MRPP2(WT/V12L/V176M) complexes were incubated and loaded onto a Superose 6 column (Fig. 4.A). The ratio of MRPP1-complexed MRPP2 vs. uncomplexed MRPP2 is similar for MRPP2(WT) and MRPP2(V12L). Nevertheless, this ratio is shifted by a third towards uncomplexed protein for MRPP2(V176M), indicating a higher tendency for the isolated MRPP1-MRPP2(V176M) complex to dissociate over time, compared to MRPP1-MRPP2(WT) and MRPP1-MRPP2(V12L).




Fig. 4. Effect of p.V12L/p.V176M mutations on tRNA processing functions of MRPP2-associated complexes (A) Size exclusion chromatography profile of MRPP1 co-expressed with

MRPP2(WT/V12L/V176M). The dashed boxes indicate the fractions from the chromatogram (top) and SDS-PAGE (bottom) where proteins form a complex, or are present as separate species in solution. (B) m¹G9 and m¹A9 methyltransferase activity of the MRPP1-MRPP2(WT/V12L/V176M) complexes. (C) RNase P activity towards mitochondrial pre-(mt)tRNA^{lle} of the MRPP complex that contains MRPP2(WT/V12L/V176M), measured by change in electrophoretic mobility between precursor and processed (mt)tRNA.

3.6 tRNA-dependent methyltransferase and endonuclease activities

The MRPP1-MRPP2(WT/V12L/V176M) complexes were next assayed for the m¹R9 methyltransferase activity towards (mt)tRNAs (Fig. 4.B) containing either guanine (G) or adenine (A) at position 9, for formation of m¹G9 or m¹A9, respectively. The m¹G9 methyltransferase activity was tested with *in vitro* transcribed pre-(mt)tRNA^{lle} as substrate, and m¹A9 activity with pre-(mt)tRNA^{Val}. MRPP1-MRPP2(V12L) showed a 2.5-fold reduction of m¹G9 methyltransferase activity and a 3.5-fold reduction in m¹A9 methyltransferase activity, compared to the wildtype complex. For MRPP1-MRPP2(V176M), almost no methyltransferase activity was observed for either m¹G9 or m¹A9 formation.

The RNase P activity towards the 5'-end of pre-(mt)tRNA was carried out by incubating the MRPP1-MRPP2(WT/V12L/V176M) complexes with purified MRPP3 (Fig. B), in the presence of Mg²⁺ (required for the cleavage reaction) and *in vitro* transcribed pre-(mt)tRNA^{lle} substrate (Fig. 4.C, left). In this assay, 60±1% of pre-(mt)tRNA^{lle} was processed by MRPP1-MRPP2(WT)-MRPP3, compared to 29±6% (2-fold decrease) for MRPP1-MRPP2(V12L)-MRPP3 and only 1.9±0.2% (> 30-fold decrease) for MRPP1-MRPP2(V176M)-MRPP3 (Fig. 4.C, right). The fold decrease of RNase P activity for the mutant ternary complexes is comparable to their identified methyltransferase activities.

4. DISCUSSION

MRPP2 is a multifunctional protein harbouring both SDR and non-SDR functions. As an SDR, MRPP2 acts on many substrates, amongst others isoleucine, sex steroids, bile acids and neurosteroids. In its non-SDR function, MRPP2 moonlights in binary and ternary protein-complexes involved in tRNA modifications. Several missense mutations are reported in the *HSD17B10* gene coding for MRPP2, and for some mutations the phenotype severity does not correlate with residual SDR activity, drawing attention to the non-SDR functions of MRPP2. In this work, two novel mutations in MRPP2 (p.V12L and p.V176M) have been identified, and characterised *in vitro*. On the whole (Table 1), both p.V12L and p.V176M mutations reduced the dehydrogenase activity of MRPP2, m¹R9 methyltransferase activity of MRPP1-MRPP2 and RNase P activity of MRPP1-MRPP2-MRPP3, albeit in varying degrees and seemingly via different molecular defects to MRPP2 protein properties.

	Dehydrogenase act.		Methyltransferase act.		RNase P act.	Complex stability	Location in structure
	[min ⁻¹ μM ⁻¹] (k _{cat} /K _M)		[cpm]		[% of total pre-(mt)tRNA]		
	CoA thioester	Steroid	Adenine	Guanine			
WT	458±17	706±13	4609±819	5238±394	60±1	Stable	
p.V12L	412±18	540±19	1258±49	2036±85	29±6	Stable	Core β-sheet
p.V176M	481±29	-	26±31	35±31	2±0.2	Unstable	Helix αE

Table 1. Outline of the residual activities measured in this report, along with the structural location and ability to form the binary complex (given as stable: complex formed, or unstable: complex dissociating) for the two novel mutations identified in MRPP2 (p.V12L and p.V176M).

We propose that the p.V12L missense mutation results in a less thermostable MRPP2 protein, reducing protein abundance that indirectly impacts on the associated enzyme functions. Val12 is situated at the beginning of strand-βA that forms part of the core Rossmann fold β-sheet. When mutated to Leu, this residue likely creates a steric clash with the nearby Arg84 main-chain and Phe82 side-chain atoms, towards the end of the helix-αC (Fig. E.1). The steric constraints could imply a rearrangement of the implicated residues that destabilise the core β-sheet and overall structure. Such destabilisation can explain the significantly lowered solubility of MRPP2(V12L) and increased tendency to aggregate compared to wildtype, although once isolated, the soluble mutant protein exhibits only a moderately reduced SDR activity. Protein

destabilisation would also affect the tRNA processing functions of MRPP2 by reducing the level of soluble mutant protein for complex formation.

We propose that the p.V176M mutation disrupts MRPP2 functions by a mechanism different from p.V12L. Val176 is located in helix- α F that contributes to one side of the substrate binding pocket (Fig. 1.C). Helix- α F is immediately followed by a loop-helix-loop segment that contains many catalytically important residues, including Gln162 and Gln165 implicated in ligand binding [34,35], Ser155 from the catalytic tetrad [36], residues involved in formation of the proton-relay system [36–38], and Ala154 and Thr153 from the cofactor binding pocket [39]. Mutation of Val176-to-Met could cause steric clashes with this loop-helix-loop segment, *i.e.* side-chains of Ala156 and the Phe159, altering positions of the catalytically important residues that result in k_{cat} and K_{M} changes to catalysis (Fig. E.2). Altogether, this supports the more pronounced effect on MRPP2 functions (dehydrogenase, methyltransferase, RNase P activities) for p.V176M, compared to p.V12L.

An inhibitory effect of both mutations on the dehydrogenase activity of MRPP2 was not only observed with purified proteins for the substrates 3-hydroxybutyryl-CoA and allopregnanolone, but also in a comparable manner with patient cells and 2-methyl-3-hydroxybutyryl-CoA. However, the higher residual activity in the cells of the patient from family 2, compared with the residual activity found for the patient from family 1, may indicate a lower severity of the *de novo* mutation p.V12L in family 2, compared with p.V176M in family 1, but may also be due to heterozygosity and/or X-inactivation (family 2) in contrast to hemizygosity (index case, family 1). In agreement with previous observations [13], clinical features in family 1 did not segregate with the mutation in the *HSD17B10* gene.

Although both mutations showed diminished cofactor binding from DSF, only MRPP2(V176M) showed an increased K_{M} -value indicative of poor substrate accommodation, possibly due to an altered active site. These alterations seem to affect the steroid substrate more than the 3-hydroxybutyryl-CoA, as shown for MRPP2(V176M). One reason for this could be the smaller molecular size of allopregnanolone (318.49 Da) compared to 3-hydroxybutyryl-CoA (853.63 Da). The smaller steroid would have fewer interaction points with the protein active site, compared to the larger CoA thioester substrate. Small changes to the pocket could therefore impact more

severely the binding of allopregnanolone, compared to 3-hydroxybutyryl-CoA, which might be compensated by additional interaction points outside the immediate active site pocket. The p.V176M mutation also caused MRPP2 to dissociate from the complex with MRPP1 more readily than wildtype, which could explain the nearly abolished m¹R9 methyltransferase and RNase P activities observed, as both of these activities require an intact complex [18]. Further structural analysis is required to elucidate how this mutation disturbs MRPP1-MRPP2 interaction, since Val176 is not surface exposed and therefore not in a location predicted to be the protein-protein interface.

ACKNOWLEDGMENTS

Technical assistance by Annegret Flier and financial support by Fondation Claude et Giuliana and Olga Mayenfisch-Stiftung is gratefully acknowledged.

FUNDING

This work was funded by the Structural Genomics Consortium, which is a registered charity (number 1097737) that receives funds from AbbVie, Boehringer Ingelheim, the Canada Foundation for Innovation, the Canadian Institutes for Health Research, Genome Canada, GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and the Wellcome Trust (092809/Z/10/Z).

DISCLOSURE STATEMENT

No potential conflicts of interest are reported for any of the authors.

REFERENCES

- [1] H. Jomvall, B. Persson, M. Krook, S. Atrian, R. González-Duarte, J. Jeffery, D. Ghosh, Short-Chain Dehydrogenases/Reductases (SDR), *Biochemistry*. 34 (1995) 6003–6013.
- [2] Y. Kallberg, U. Oppermann, H. Jörnvall, B. Persson, Short-chain dehydrogenase/reductase (SDR) relationships : A large family with eight clusters common to human, animal, and

- plant genomes, *Protein Sci.* 11 (2002) 636–641. doi:10.1110/ps.26902.spite.
- [3] K.L. Kavanagh, H. Jörnvall, B. Persson, U. Oppermann, Medium- and short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes., *Cell. Mol. Life Sci.* 65 (2008) 3895–906. doi:10.1007/s00018-008-8588-y.
- [4] S.-Y. Yang, X.-Y. He, S.E. Olpin, V.R. Sutton, J. McMenamin, M. Philipp, R.B. Denman, M. Malik, Mental retardation linked to mutations in the HSD17B10 gene interfering with neurosteroid and isoleucine metabolism., *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 14820–4. doi:10.1073/pnas.0902377106.
- [5] X. He, G. Merz, P. Mehta, H. Schulz, S. Yang, Human Brain Short Chain l-3-Hydroxyacyl Coenzyme A Dehydrogenase Is a Single-domain Multifunctional Enzyme: Characterization of a novel 17 β -hydroxysteroid dehydrogenase, *J. Biol. Chem.* 274 (1999) 15014–15019.
- [6] X. He, Y. Yang, H. Schulz, S. Yang, Intrinsic alcohol dehydrogenase and hydroxysteroid dehydrogenase activities of human mitochondrial short-chain, 345 (2000) 139–143.
- [7] N. Shafqat, H.-U. Marschall, C. Filling, E. Nordling, X.-Q. Wu, L. Björk, J. Thyberg, E. Mårtensson, S. Salim, H. Jörnvall, U. Oppermann, Expanded substrate screenings of human and *Drosophila* type 10 17 β -hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: characterization of multifunctional 3 α /7 α /7 β /17 β /20 β /21-H, *Biochem. J.* 376 (2003) 49–60. doi:10.1042/BJ20030877.
- [8] X.-Y. He, J. Wegiel, Y.-Z. Yang, R. Pullarkat, H. Schulz, S.-Y. Yang, Type 10 17 β -hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors., *Mol. Cell. Endocrinol.* 229 (2005) 111–7. doi:10.1016/j.mce.2004.08.011.
- [9] M.J. Luo, L.-F. Mao, H. Schulz, Short-chain 3-Hydroxy-2-methylacyl-CoA Dehydrogenase from Rat Liver: Purification and Characterization of a Novel Enzyme of Isoleucine Metabolism, *Biochem. Biophys.* 321 (1995) 214–220.
- [10] X. He, H. Schulz, S.-Y. Yang, A Human Brain l-3-Hydroxyacyl-coenzyme A Dehydrogenase Is Identical to an Amyloid β -Peptide-binding Protein Involved in Alzheimers Disease, J.

- Biol. Chem. 273 (1998) 10741–10746.
- [11] U. Oppermann, S. Salim, L.O. Tjernberg, L. Terenius, H. Jörnvall, Binding of amyloid β -peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): Regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease, *FEBS Lett.* 451 (1999) 238–242. doi:10.1016/S0014-5793(99)00586-4.
 - [12] J. Zschocke, HSD10 disease: clinical consequences of mutations in the HSD17B10 gene., *J. Inherit. Metab. Dis.* 35 (2012) 81–9. doi:10.1007/s10545-011-9415-4.
 - [13] K. Rauschenberger, K. Schöler, J.O. Sass, S. Sauer, Z. Djuric, C. Rumig, N.I. Wolf, J.G. Okun, S. Kölker, H. Schwarz, C. Fischer, B. Grziwa, H. Runz, A. Nümann, N. Shafqat, K.L. Kavanagh, G. Hämmerling, R.J. a Wanders, J.P.H. Shield, U. Wendel, D. Stern, P. Nawroth, G.F. Hoffmann, C.R. Bartram, B. Arnold, A. Bierhaus, U. Oppermann, H. Steinbeisser, J. Zschocke, A non-enzymatic function of 17 β -hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival., *EMBO Mol. Med.* 2 (2010) 51–62. doi:10.1002/emmm.200900055.
 - [14] A.J. Deutschmann, A. Amberger, C. Zavadil, H. Steinbeisser, J. a Mayr, R.G. Feichtinger, S. Oerum, W.W. Yue, J. Zschocke, Mutation or knock-down of 17 β -hydroxysteroid dehydrogenase type 10 cause loss of MRPP1 and impaired processing of mitochondrial heavy strand transcripts., *Hum. Mol. Genet.* (2014) 1–11. doi:10.1093/hmg/ddu072.
 - [15] J. Holzmann, P. Frank, E. Löffler, K.L. Bennett, C. Gerner, W. Rossmanith, RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme, *Cell.* 135 (2008) 462–474. doi:10.1016/j.cell.2008.09.013.
 - [16] V. Anantharaman, E. V Koonin, L. Aravind, SPOUT : a Class of Methyltransferases that Includes spoU and trmD RNA Methylase Superfamilies , and Novel Superfamilies of Predicted Prokaryotic RNA Methylases, *J. Mol. Microbiol. Biotechnol.* 4 (2002) 71–75.
 - [17] V. Anantharaman, L. Aravind, The NYN Domains Novel Predicted RNases with a PIN Domain-Like Fold, *RNA Biol.* 3 (2006) 18–27.
 - [18] E. Vilardo, C. Nachbagauer, A. Buzet, A. Taschner, J. Holzmann, W. Rossmanith, A subcomplex of human mitochondrial RNase P is a bifunctional methyltransferase--extensive moonlighting in mitochondrial tRNA biogenesis., *Nucleic Acids Res.* 40 (2012)

- 11583–93. doi:10.1093/nar/gks910.
- [19] M. Helm, H. Brulé, F. Degoul, C. Cepanec, J.P. Leroux, R. Giegé, C. Florentz, The presence of modified nucleotides is required for cloverleaf folding of a human mitochondrial tRNA, *Nucleic Acids Res.* 26 (1998) 1636–1643. doi:10.1093/nar/26.7.1636.
- [20] F. Voigts-Hoffmann, M. Hengesbach, A.Y. Kobitski, A. Van Aerschot, P. Herdewijn, G. Ulrich Nienhaus, M. Helm, A methyl group controls conformational equilibrium in human mitochondrial tRNA^{Lys}, *J. Am. Chem. Soc.* 129 (2007) 13382–13383. doi:10.1021/ja075520+.
- [21] L.M. Wittenhagen, S.O. Kelley, Impact of disease-related mitochondrial mutations on tRNA structure and function., *Trends Biochem. Sci.* 28 (2003) 605–11. doi:10.1016/j.tibs.2003.09.006.
- [22] L.H. Seaver, X.-Y. He, K. Abe, T. Cowan, G.M. Enns, L. Sweetman, M. Philipp, S. Lee, M. Malik, S.-Y. Yang, A novel mutation in the HSD17B10 gene of a 10-year-old boy with refractory epilepsy, choreoathetosis and learning disability., *PLoS One.* 6 (2011) e27348. doi:10.1371/journal.pone.0027348.
- [23] R. Ofman, J.P.N. Ruiter, M. Feenstra, M. Duran, B.T. Poll-The, J. Zschocke, R. Ensenauer, W. Lehnert, J.O. Sass, W. Sperl, R.J. a Wanders, 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene., *Am. J. Hum. Genet.* 72 (2003) 1300–7. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1180283&tool=pmcentrez&rendertype=abstract>.
- [24] J. Zschocke, J.P. Ruiter, J. Brand, M. Lindner, G.F. Hoffmann, R.J. Wanders, E. Mayatepek, Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism., *Pediatr. Res.* 48 (2000) 852–5. doi:10.1203/00006450-200012000-00025.
- [25] T. Fukao, K. Akiba, M. Goto, N. Kuwayama, M. Morita, T. Hori, Y. Aoyama, R. Venkatesan, R. Wierenga, Y. Moriyama, T. Hashimoto, N. Usuda, K. Murayama, A. Ohtake, Y. Hasegawa, Y. Shigematsu, Y. Hasegawa, The first case in Asia of 2-methyl-3-

- hydroxybutyryl-CoA dehydrogenase deficiency (HSD10 disease) with atypical presentation, *J. Hum. Genet.* 59 (2014) 609–614. doi:10.1038/jhg.2014.79.
- [26] S. Akagawa, T. Fukao, Y. Akagawa, H. Sasai, U. Kohdera, M. Kino, Y. Shigematsu, Y. Aoyama, K. Kaneko, Japanese Male Siblings with 2-Methyl-3-Hydroxybutyryl- CoA Dehydrogenase Deficiency (HSD10 Disease) Without Neurological Regression, *JIMD Rep.* (2016) 113–116. doi:10.1007/8904.
- [27] J. García-Villoria, A. Navarro-Sastre, C. Fons, C. Pérez-Cerdá, A. Baldellou, M.A. Fuentes-Castelló, I. González, A. Hernández-Gonzalez, C. Fernández, J. Campistol, C. Delpiccolo, N. Cortés, A. Messeguer, P. Briones, A. Ribes, Study of patients and carriers with 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: difficulties in the diagnosis., *Clin. Biochem.* 42 (2009) 27–33. doi:10.1016/j.clinbiochem.2008.10.006.
- [28] M.J. Falk, X. Gai, M. Shigematsu, E. Vilardo, R. Takase, E. McCormick, T. Christian, E. Place, E.A. Pierce, M. Consugar, H.B. Gamper, W. Rossmanith, Y.-M. Hou, A novel HSD17B10 mutation impairing the activities of the mitochondrial RNase P complex causes X-linked intractable epilepsy and neurodevelopmental regression, *RNA Biol.* 13 (2016) 477–485. doi:10.1080/15476286.2016.1159381.
- [29] C. Perez-Cerda, J. García-Villoria, R. Ofman, P.R. Sala, B. Merinero, J. Ramos, M.T. García-Silva, B. Beseler, J. Dalmau, R.J. a Wanders, M. Ugarte, A. Ribes, 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: an X-linked inborn error of isoleucine metabolism that may mimic a mitochondrial disease., *Pediatr. Res.* 58 (2005) 488–91. doi:10.1203/01.pdr.0000176916.94328.cd.
- [30] C.F. Lorea, A. Sitta, R. Yamamoto, F.P.A. Paulo, P.F. Vairo, C.R.M. Rieder, M. Wajner, I.V.D. Schwartz, R. Giugliani, L.B. Jardim, J.O. Sass, J.A. Saute, Case report: atypical juvenile parkinsonism and basal ganglia calcifications due to HSD10 disease, *Abstr. J Inherit Metab Dis.* 38 (2015) 210.
- [31] E. Vilardo, W. Rossmanith, Molecular insights into HSD10 disease: impact of SDR5C1 mutations on the human mitochondrial RNase P complex, *Nucleic Acids Res.* (2015) 1–9. doi:10.1093/nar/gkv408.
- [32] F.H. Niesen, H. Berglund, M. Vedadi, The use of differential scanning fluorimetry to

- detect ligand interactions that promote protein stability., *Nat. Protoc.* 2 (2007) 2212–2221. doi:10.1038/nprot.2007.321.
- [33] C.R. Kissinger, P. a Rejto, L. a Pelletier, J. a Thomson, R.E. Showalter, M. a Abreo, C.S. Agree, S. Margosiak, J.J. Meng, R.M. Aust, D. Vanderpool, B. Li, A. Tempczyk-Russell, J.E. Villafranca, Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics., *J. Mol. Biol.* 342 (2004) 943–52. doi:10.1016/j.jmb.2004.07.071.
- [34] A.. Powell, J.. Read, M.. Banfield, F. Gunn-Moore, S.. Yan, J. Lustbader, A.. Stern, D.. Stern, R.. Brady, Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/Amyloid- β binding alcohol dehydrogenase (ABAD), *J. Mol. Biol.* 303 (2000) 311–327. doi:10.1006/jmbi.2000.4139.
- [35] S.-Y. Yang, X.-Y. He, C. Isaacs, C. Dobkin, D. Miller, M. Philipp, Roles of 17 β -hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders, *J. Steroid Biochem. Mol. Biol.* 143 (2014) 460–472. doi:10.1016/j.jsbmb.2014.07.001.
- [36] C. Filling, K.D. Berndt, J. Benach, S. Knapp, T. Prozorovski, E. Nordling, R. Ladenstein, H. Jörnvall, U. Oppermann, Critical residues for structure and catalysis in short-chain dehydrogenases/reductases., *J. Biol. Chem.* 277 (2002) 25677–84. doi:10.1074/jbc.M202160200.
- [37] U.C. Oppermann, C. Filling, H. Jörnvall, Forms and functions of human SDR enzymes., *Chem. Biol. Interact.* 130–132 (2001) 699–705. <http://www.ncbi.nlm.nih.gov/pubmed/11306087>.
- [38] R. Ladenstein, J.O. Winberg, J. Benach, Medium- and short-chain dehydrogenase/reductase gene and protein families: Structure-function relationships in short-chain alcohol dehydrogenases, *Cell. Mol. Life Sci.* 65 (2008) 3918–3935. doi:10.1007/s00018-008-8590-4.
- [39] A.C. Wallace, R.A. Laskowski, J.M. Thornton, LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions, *Protein Eng.* 8 (1995) 127–134. doi:10.1093/protein/8.2.127.

